About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Fbxo43tm1.2Kald
targeted mutation 1.2, Philipp Kaldis
MGI:6201342
Summary 3 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Fbxo43tm1.2Kald/Fbxo43tm1.2Kald involves: 129 * C57BL/6 * FVB/N * SJL MGI:6201524
cn2
Fbxo43tm1.1Kald/Fbxo43tm1.2Kald
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL MGI:6201521
cn3
Cdk1tm3Kald/Cdk1+
Fbxo43tm1.2Kald/Fbxo43tm1.2Kald
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL MGI:6201527


Genotype
MGI:6201524
hm1
Allelic
Composition
Fbxo43tm1.2Kald/Fbxo43tm1.2Kald
Genetic
Background
involves: 129 * C57BL/6 * FVB/N * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Fbxo43tm1.2Kald mutation (0 available); any Fbxo43 mutation (29 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
reproductive system
• with a germinal vesicle-like structure with chromatin (likely decondensed)
• absence of spermatid at p63 and sperm in epididymis at P120
• arrested in metaphase meiosis II
• parthenogenetic divisions in oocytes of 2 of 11 mice
• in prophase in meiosis I
• however, meiotic recombination and resolution of double-strand breaks is normal
• at stage XII (pachytene/diplotene)

neoplasm
N
• despite parthenogenetic oocyte divisions, female mice do not develop ovarian cancer

endocrine/exocrine glands

cellular
• with a germinal vesicle-like structure with chromatin (likely decondensed)
• absence of spermatid at p63 and sperm in epididymis at P120
• arrested in metaphase meiosis II
• parthenogenetic divisions in oocytes of 2 of 11 mice
• in prophase in meiosis I
• however, meiotic recombination and resolution of double-strand breaks is normal
• at stage XII (pachytene/diplotene)




Genotype
MGI:6201521
cn2
Allelic
Composition
Fbxo43tm1.1Kald/Fbxo43tm1.2Kald
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Fbxo43tm1.1Kald mutation (0 available); any Fbxo43 mutation (29 available)
Fbxo43tm1.2Kald mutation (0 available); any Fbxo43 mutation (29 available)
Gt(ROSA)26Sortm1(cre/ERT)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
reproductive system
• at stage XII (pachytene/diplotene) in tamoxifen-treated mice
• in tamoxifen-treated mice

cellular
• at stage XII (pachytene/diplotene) in tamoxifen-treated mice




Genotype
MGI:6201527
cn3
Allelic
Composition
Cdk1tm3Kald/Cdk1+
Fbxo43tm1.2Kald/Fbxo43tm1.2Kald
Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdk1tm3Kald mutation (0 available); any Cdk1 mutation (21 available)
Fbxo43tm1.2Kald mutation (0 available); any Fbxo43 mutation (29 available)
Gt(ROSA)26Sortm1(cre/ERT)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• within 4 to 5 days after treatment with tamoxifen at around age P21

reproductive system
• after treatment with tamoxifen at around age P21
• early in diplotene with some progression into metaphase
• after treatment with tamoxifen at around age P21

cellular
• after treatment with tamoxifen at around age P21
• early in diplotene with some progression into metaphase
• after treatment with tamoxifen at around age P21





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
11/19/2024
MGI 6.24
The Jackson Laboratory